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Abstract
Alzheimer’s Disease (AD) is characterized by the cerebral accumulation of misfolded and aggregated
amyloid-β protein (Aβ). Disease symptoms can be alleviated, in vitro and in vivo, by “β-sheet
breaker” pentapeptides that reduce plaque volume. However the peptide nature of these compounds,
made them biologically unstable and unable to penetrate membranes with high efficiency. The main
goal of this study was to use computational methods to identify small molecule mimetics with better
drug-like properties. For this purpose, the docked conformations of the active peptides were used to
identify compounds with similar activities. A series of related β-sheet breaker peptides were docked
to solid state NMR structures of a fibrillar form of Aβ. The lowest energy conformations of the active
peptides were used to design three dimensional (3D)-pharmacophores, suitable for screening the NCI
database with Unity. Small molecular weight compounds with physicochemical features in a
conformation similar to the active peptides were selected, ranked by docking solubility parameters.
Of 16 diverse compounds selected for experimental screening, 2 prevented and reversed Aβ
aggregation at 2–3 μM concentration, as measured by Thioflavin T (ThT) fluorescence and ELISA
assays. They also prevented the toxic effects of aggregated Aβ on neuroblastoma cells. Their low
molecular weight and aqueous solubility makes them promising lead compounds for treating AD.
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1. Introduction
Alzheimer’s Disease (AD) is the most common form of dementia in the elderly, affecting 6–
10% of people over the age of 651. A progressive neurodegenerative disease2, AD’s clinical
symptoms include personality and behavioral changes, periods of disorientation, difficulty
communicating, and gradual loss of memory. Although the molecular basis of AD has been
extensively studied, there is still no early diagnosis or cure. The hallmark neuropathological
features of the disease are the accumulation of extracellular plaques composed of the amyloid-
β protein (Aβ), and intracellular, hyper-phosphorylated tau forming neurofibrillary tangles and
dystrophic neurites. The progression of Aβ plaque deposition in humans begins in the temporal
cortex, proceeds to the hippocampus and then to the entorhinal and transentorhinal cortexes3,
while tau deposits progress in the opposite direction4. Several possible molecular mechanisms
may initiate AD. However, considerable genetic and biochemical evidence suggests that the
Aβ misfolding, oligomerization and accumulation in the brain is the primary cause of the
neuronal dysfunction5.
Amyloid is a generic term used to refer to protein aggregates adopting a cross-β-sheet
structure6. Several studies have shown that the aggregation and fibril formation of Aβ involves
a change in conformation, from a (soluble) helical or coiled structure to an insoluble oligomer
7. Solid state NMR studies of 6–10 nm in diameter fibrils of purified Aβ have revealed an
underlying superstructure of anti-parallel intra-molecular β-strands stabilized predominantly
by backbone hydrogen bonds and salt bridges, and parallel, inter-molecular β-sheets stabilized
predominantly by backbone hydrogen bonds and hydrophobic interactions8–11. A network of
inter- and intra- molecular hydrogen bonds maintains the stability of the fibril once it has
formed12–15. Aβ can form amyloid-like fibrils in the absence of other proteins7, indicating that
the potential to form amyloid originates within its own sequence. Substitution of hydrophilic
for hydrophobic residues in the central hydrophobic region of Aβ (17 to 21) impairs fibril
formation12, 16–21, and peptides designed to mimic the structure of this region could inhibit
aggregation. A series of “β-sheet breaker peptides” were designed based on Aβ amino acids17–
20 (LVFFD), and then chemically modified to obtain more active and stable pentapeptides
with the basic sequence LPFFD22–25. Such compounds were demonstrated by us and other
groups to be active in destabilizing the pathological Aβ conformation, leading to both inhibition
of amyloid formation and disassembly of pre-formed fibrils. The lead β-sheet breaker peptide
is able to inhibit and disassemble amyloid fibrils in vitro, to prevent Aβ neurotoxicity in cell
culture, and to arrest and dissolve amyloid plaques in several in vivo animals models23, 24,
26. Treatment with this peptide also inhibited neuronal death, brain inflammation and memory
impairment in vivo23, 24. In addition, the modified peptide showed low toxicity, low
immunogenicity, high solubility and reasonably high brain uptake23, 25. In spite of the good
activity in vivo, the major weaknesses of this peptide are that it is rapidly degradable and has
low permeability to cross biological barriers25. These are serious limitations because a more
frequent administration of large quantities by inconvenient routes (injection) is likely to be
necessary. It may also be difficult or impossible to reach the appropriate doses for anti-amyloid
activity in the large volume of the human brain.
The major goal of the current study is to use the knowledge accumulated over several years on
the structure-activity relationship studies of β-sheet breaker peptides and their 3-dimensional
structure to design and identify small molecule peptidemimetic compounds. For this purpose,
we used a computational/docking approach to identify features of this peptide series that
correlated with their ability to prevent Aβ aggregation. We docked the peptide series to the
fibrillar structures of Aβ determined from solid state NMR data. While the docking energies
could not be used to discriminate the best inhibitors of aggregation, active peptides
preferentially bound to different sites on the fibril from those favored by inactive ones. We
used the docked conformations of the peptides to obtain a 3D-molecular pharmacophore, which
Chen et al. Page 2
Bioorg Med Chem. Author manuscript; available in PMC 2010 July 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
could be used with the UNITY program to screen the NIH library for compounds with the
desired physicochemical properties. These were initially ranked based on number of
pharmacophores they matched and then by molecular docking to the experimentally
determined structures of fibrillar Aβ. The compounds with the best docking scores at the
optimal peptide positions were further selected for solubility (low logP: the coefficient for
solvent partitioning between 1-octanol and water), and low molecular weight. Finally, 16
compounds from the NCI library27 (http://dtp.nci.nih.gov/webdata.html) were selected and
assayed for their ability to inhibit and reverse the aggregation of Aβ, in three different assays,
and the toxic effects of aggregates on neuronal cells. Two compounds inhibited Aβ aggregation
and cytotoxicity to neuroblastoma cells. They are thus promising lead compounds for
developing novel treatments for AD.
2. Results
2.1 Docking of β-sheet breaker peptides and selected compounds to the Aβ fibril
We first docked β-sheet breaker peptides to the fibril structures, to relate binding energies to
their activities in disaggregating Aβ. Thirty pentapeptides, with known and varying ability to
inhibit Aβ aggregation, were initially docked to the larger grid box (see Experimental 5.2, 5.3),
to find the site on the fibril for which they had the highest affinity. While the peptides all had
similar Autodock scores (Table S1, supplementary), their preferred docking sites were quite
different (Fig. 1). The most active peptides (red; peptides with relative activities > 70 in
Supplementary Material Table 1s) bound to a few sites on each fibril structure, while the
inactive ones showed less specificity. The first preferred docking site includes residues
GLU11-PHE19 and LEU34-VAL40 of 4 outer neighbor monomers. The second preferred
docking site includes residues 37–39 from the upper 6 monomers and residues 28–32 from the
bottom 6 monomers.
For pharmacophore design and compound docking, two optimal binding (Fig. 2) were selected
for each fibril model. The first binding sites, where LPFFD has the best AutoDock score to the
Aβ fibril models Aβ40m2_1.pdb and Aβ40p2_1.pdb, are the same as the preferred docking
sites shown in Fig. 1. The second binding site chosen is that with the next lowest docking
energy that is at least 15Å away from the first site. The second binding sites for both fibril
structures, Aβ40m2_1.pdb and Aβ40p2_1.pdb, are close to the docking site of DFPPL to Aβ
identified by NMR28, which primarily interacted with residues Lys16-Phe20 on the top surface
of several monomers. The most active β-sheet breaker pentapeptides25 bind around site 1 in
both structures. For comparison purposes, all 30 compounds were also docked to two binding
sites on the Aβ40m2_1.pdb and Aβ40p2_10.pdb models (Fig. 2). Theses sites were also later
used to determine the docking energy of compounds selected from NCI database (to match the
pharmacophores). Based on the docking results, active compounds, including the lead
compound LPFFD which is used for pharmacophore design, can form hydrogen bonds with
the backbone hydrogen bond forming atoms. We will discuss the preferred interactions
between the active compounds and the fibril later.
2.2 Pharmacophore Design
We assumed that the preferred docking sites for the active peptides represented optimal binding
positions on the Aβ fibril. The pattern of bonds formed by LPFFD with the fibril in the lowest
energy docked conformation were analyzed, to derive features and distance constraints for the
design of four 3D-pharmacophores, based on docking to Aβ40m2_1.pdb and Aβ40p2_1.pdb
at sites 1 and 2 (Fig. 3).
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2.3 Database Screening with UNITY
The pharmacophores were used with the UNITY program to search ~250,000 structures from
the NCI library. The numbers of compounds that match each of the four 3D-pharmacophores
were 980, 1130, 1720 and 1440 for pharmacophore 1, 2 3 and 4 respectively. These were docked
to the Aβ fibril structures at sites 1 and 2. The number of compounds with lower docking
energies than LPFFD was 68, 26, 61 and 33 for site 1 of Aβ40m2_1.pdb, site 2 of
Aβ40m2_1.pdb, site 1 of Aβ40p2_1.pdb and site 2 of Aβ40p2_1.pdb respectively. We further
reduced the number of compounds for assay by giving highest priority to compounds selected
by UNITY as a potential match for multiple pharmacophores (27 compounds were identified
as similar to all 4 pharmacophores, 42 were found in 3 of the 4, 105 in 2, and the remaining
4800 compounds matched only one pharmacophore).
We chose 31 compounds with higher calculated docking affinities than LPFFD from the 69
compounds that matched at least 3 pharmacophores. Although we knew from the peptide series
that docking energies alone are not sufficient to distinguish the active peptides from the inactive
ones, it was also clear that to reverse the aggregation, an inhibitor should preferentially bind
Aβ. Of these, 16 were selected based on their physical properties (logP is not over 5, molecular
weight is not over 500, number of hydrogen bond acceptors (HBA) is not over 10, and hydrogen
bond donors (HBD) is not over 5). If two or more parameters were out of range, the compounds
would not be selected. The structure of the 16 compounds and their NCI number are shown in
Figure 4. Table 1 lists their docking scores and physicochemical properties.
2.4. Bioassays
The selected molecules were first screened using a medium throughput in vitro assay based on
the specific interaction between amyloid fibrils and ThT. Incubation of soluble Aβ alone for
24h resulted in extensive formation of amyloid fibrils (Fig. 5). However, co-incubation with
an equimolar concentration of several of the compounds led to a highly significant inhibition
of fibril formation. Two compounds, termed BSBM6 and BSBM7 (beta-sheet breaker mimetic
6 and 7, respectively, Fig. 5a), were selected for further studies, since they showed the highest
reproducible inhibition in all assays. Equimolar concentration of these compounds led to >70%
inhibition of fibril formation (Fig. 5b). In contrast, an inactive compound (C1 from the initial
series) did not alter Aβ amyloidogenesis at the concentration studied. BSBM 6 and 7 were also
able to disassemble pre-formed Aβ fibrils (Fig. 5C), decreasing the amount of pre-formed
fibrils by >70%. Again, C1 did not alter significantly the amount of fibrils. As controls the
compounds alone were added to the ThT assay and the results showed that none of the
compounds studied altered ThT fluorescence (data not shown). To confirm the results using
an in vitro assay based on a different principle, and to assess the concentration-dependent effect
of the compounds in Aβ aggregation, we measured the compounds’ activity using a
sedimentation assay, and measured the amount of Aβ using an ELISA assay. Increasing
concentrations of BSBM6 or BSBM7 inhibited aggregation, reaching a maximum of around
80% at approximately around equimolarity with the Aβ concentration (4 μM; Fig. 5D). The
IC50 values for BSBM6 and BSBM7 in this assay are 2.75 and 1.95 μM, respectively.
2.5. BSBM6 and 7 reduce the neurotoxicity of Aβ aggregates
Aβ aggregates decrease the viability of cultured N2A mouse neuroblastoma cells (Fig. 6).
Treatment with Aβ pre-incubated for 24h, which contain a mixture of oligomeric and fibrillar
species, substantially reduced cell viability. This effect could be prevented if the Aβ was
incubated with equimolar concentrations of BSBM6 and 7, indicating that formation of toxic
forms of misfolded Aβ was substantially inhibited. The control compound 1 did not prevent
Aβ cytotoxicity and indeed, may have increased cell death. None of the compounds tested, on
their own, were significantly toxic to cells (as measured by the MTS assay) even at quantities
10 times higher than the active concentration (data not shown).
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3. Discussion
There have been extensive studies of the mechanism of Aβ misfolding and aggregation20, 29,
30, and many different compounds have been identified that interfere with this pathway (for
reviews, see 31–35). We previously reported that Aβ fibrillogenesis can be prevented and
reversed by short peptides designed to bind and inhibit β-sheet misfolding of Aβ (β-sheet
breaker peptides). These peptides are active in vitro, in cells and in several in vivo animal
models of AD22–26 Moreover, they are well-tolerated in humans, although they exhibited a
short half-life and are not orally bioavailable25. Using the knowledge gained about the
structure-activity relationships of the peptide series, we used computational modeling and
docking techniques to study the interaction with Aβ the peptide series, and relate the
interactions of their sidechains to their different activities in preventing aggregation (Figs 1–
2, Supplementary data table 1s). The purpose of this study was to identify small molecule
peptide mimetics capable to maintain the ability to inhibit and reverse Aβ misfolding and
aggregation, but with better drug-like properties. We identified two sites on the fibril structure
where the most active peptides bound preferentially. As β-sheet breakers bind to the fibril at
different positions and the fibril may have different conformations, we used the
pharmacophores (schematic structures of an ideal small molecule inhibitor) from the 3D-
quantitative structure-activity relationship (3D-QSAR; the crossvalidated r2 (q2) for the β-sheet
breakers is only about 0.5) only as approximate guidance for the relative positioning of reactive
groups. To obtain more detailed 3D-pharmacophores, we relied on docked conformations of
the active peptides with the fibril structure (Fig. 3). These were used to screen the NCI database,
a diverse library which includes many drug like molecules, for potential aggregation inhibitors.
A small group of compounds were then selected for testing in a medium throughput assay
(Table 1), and two compounds identified as consistently active in preventing and reversing
Aβ fibrillogenesis (Fig. 5), measured in three different ways, and blocking Aβ neurotoxicity
(Fig. 6). For these initial experiments, we used the smaller NCI database. Now that we have a
better idea of what constitutes an active aggregation inhibitor, larger databases such as. ZINC
(http://zinc.docking.org), may be used for future investigations.
The basis for this study was previous work, where we used pharmacophore design and
Autodock to find small compounds that bound to the Anthrax edema factor36, 37. Autodock
was quite accurate in finding the conformation and docking position of substrate analogues
(i.e., the docked conformation matched the conformation determined by X-ray crystallography)
37. However, docking energies were only approximate indicators of activity36, 37. Here, we
faced a more difficult challenge, as we had several possible structures for the Aβ fibril, and
only indirect evidence for where aggregation inhibitors should bind. Moreover, we knew from
the peptide data that we could not rely on docking/binding energies to indicate which inhibitors
would be most active in inhibiting the aggregation of Aβ. We thus decided to select molecules
that resembled the docked conformations of the most active peptides, and then test molecules
that had good molecular properties, and similar or higher calculated binding affinities for these
sites. A summary of our data indicates that the molecule with the highest calculated binding
affinity (first in Table 1) was a very poor inhibitor, and indeed was later used as a negative
control. Our two best inhibitors had only slightly better binding affinity than the best β-sheet
breaker peptides. This illustrates the complexity of using calculated binding energies to identify
inhibitors of the aggregation process, and the need for experimental data to direct the selection
process.
One explanation for our results would be that our good inhibitors, such as the peptide LPFFD
and BSBM6 and BSBM7, interfere with electrostatic interactions during aggregation38 or
destabilize the Aβ-fibril internal hydrogen bond network, necessary to maintain the β-sheet
structure, by forming strong hydrogen bonds with the Aβ subunits. The lowest energy docked
conformations of active compounds, such as the peptide LPFFD, and BMBS6 and BMBS7,
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show hydrogen bonds (red arrows in Fig 7C for BSBM7 and 7D for LPFFD) that would
compete with inter-monomer ones. These hydrogen bonds between the ligand and the fibril
would be expected to weaken or break the hydrogen bond network stabilizing the sheets, and
thereby inhibit or reverse aggregation of Aβ. While C1 has high affinity for the fibril, according
to the docking scores, one reason for inactivity could be that the large multi-cyclic part of C1
(Fig. 5, top right) could also nucleate the formation of even larger aggregates. Continuing with
our analysis, inactive compounds such as C1 and the inactive peptide LTicFFD (please see
table S1) form hydrogen bonds with atoms of Aβ that do not form network stabilizing bonds
with neighboring monomers (blue arrows in Fig 7A, B). Thus, we hypothesize base on docking
that our active compounds interfere with bonds needed to maintain the inter-monomer sheets,
while the inactive ones do not. Molecular dynamic simulations for C1, LPFFD, LHFFD,
BMBS6 and BMBS7 (in preparation) show that the active compounds bind more strongly to
the fibril than inactive ones. This result agrees with a study by Bernard Reif’s group28 on the
interaction of Aβ fibrils with two peptides, a good inhibitor (LPFFD) and a weak one (DPFFL)
which showed clearly that DPFFL had a much higher on/off rate (in both Biacore and NMR
studies).
These results indicate that molecular docking can be used to discriminate features of
compounds that are important for activity, even when the overall docking energies do not
directly correlate with activity. Considering the success of the first screening, we plan to
redesign the active compounds to further analyze the role of substituents in aggregation. In
future work, we will also analyze the calculated H-bond networks of the docked conformation
of the compounds that meet our structural criteria, and use this information to select compounds
for experimental testing. This approach should lead to the identification of potent and specific
β-sheet breaker mimetics to inhibit and reverse Aβ misfolding and oligomerization and thus
offer a new avenue for developing drugs for AD treatment.
4. Conclusions
This work’s major significance is that the two compounds we identified, that inhibit and reverse
Aβ aggregation and neurotoxicity, are possible lead compounds for AD treatment, as they are
easy to produce and have low toxicity to cells. Two of the 16 compounds inhibited aggregation
at less than equimolar concentration with Aβ in the assay, in the range of 2–3 μM. The
compounds showed good activity in four different set of experiments, with different methods
for measuring aggregates: in preventing aggregation of soluble Aβ, measured by ThT
fluorescence or by centrifugation followed by quantitation with ELISA, in disaggregating
preformed Aβ fibrils, and in inhibiting the neurotoxic effects of Aβ on cultured neuroblastoma
cells. Indeed, as our least active compound (the C1 control in the assay of Figures 5 and 6) had
the most favorable (lowest) docking score, we conclude that we must analyze not just how
many bonds a compound is capable of forming with the aggregate, a number summarized
broadly in docking scores, but also what effect those bonds will have on destabilizing the inter-
subunit contact areas.
The next phase of our work will be to better define the mechanism by which our active
compounds inhibit and reverse the aggregation of Aβ. One way will be to test variations on
our active compounds that, according to their docked structures, form bonds that should
destabilize the aggregates. Additional data on the position of the ligands on the fibril, for
example from solid state NMR, would also aid in our search for more active derivatives
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5. Experimental
5.1. Structural Model Selection for Amyloid Beta Peptides
The docking targets were fibril structures of Aβ1–40, prepared in a fashion similar to the
methods for inducing aggregation of Aβ used for the experiments below, determined with solid
state NMR8–11. TEM images and MPL data from STEM images of Aβ1–42 are very similar
to those of agitated Aβ1–40 fibrils, suggesting that the structure of fibril Aβ1–42 is very similar
to Aβ1–4039. PDB-formatted files for these fibril structures were obtained directly from Dr.
Robert Tycko at the NIH (Aβ40m2_1.pdb, and Aβ40p2_1.pdb, which differ in the orientation
of the strands). The structures of Aβ40m2_1.pdb and Aβ40p2_1.pdb are different in the
monomer stacking within the β-sheets11. Conformational data were available for residues from
Gly9 to Val40; residues 1–8 were highly disordered. The conformation of a (weak) β sheet
breaker peptide, DPFFL, bound to fibrillar Aβ1–40, determined using transferred nuclear
Overhauser effect (trNOE) and transferred residual dipolar couplings (trRDC) were used for
reference28.
5.2. Inhibitor Peptides for Docking
Activity data for a group of peptides related to LPFFD and DPFFL were previously
published25 (supplementary data, table 1, which also includes their docking energies).
5.3. Docking and Scoring
Selection of the optimal docking site for the active peptide series on the NMR fibril structures
Aβ40m2_1.pdb and Aβ40p2_1.pdb was done with AutoDock
http://www.scripps.edu/mb/olson/doc/autodock) 40, 41(version 3.0.5), using the “Lamarckian”
genetic algorithm (LGA). To allow the ligands to rotate freely over the whole structure to
determine the approximate region of preferred docking to the fibril, the grid box size was set
initially to 120 × 110 × 90 points with grid spacing of 0.60Å and centered on the center of the
Aβ fibril. The optimal site on the fibril for each peptide was refined by repeating the docking
with a smaller grid box (either 60 × 60 × 60 or 80 × 80 × 80 points with grid spacing of 0.375Å.
During docking, the Aβ fibril was kept rigid and 200 conformations of the flexible ligand
peptide (LPFFD and related) were searched and docked. Other parameters were default, except
the population size (100). AutoDock docking energy, which estimates the intermolecular
potential energy between the ligand and Aβ and the torsional free energy of ligand, was
minimized.
5.4. 3D-Pharmacophore Design
Our previous work showed that AutoDock is quite accurate in positioning molecules on a given
target and determining lowest energy conformations37. Pharmacophores representing an
optimal configuration of the active groups of the active peptides were derived, with distance
constrainst obtains from the lowest energy docking conformations of LPFFD on the two Aβ
models Aβ40m2_1.pdb and Aβ40p2_10.pdb. The pharmacophore features, such as HBA
(including negatively charged groups), HBD (including postively charged groups), and
hydrophobic (HP), were defined manually based on the interactions of LPFFD with the Aβ
fibril. A hydrogen bond interaction was defined if any atom of LPFFD was within (2.8Å) of
any atom of the fibril. HP was defined if the hydrophobic groups or atoms of the ligands were
close (<4.0Å) to the hydrophobic groups or atoms of Aβ.
5.5 Database Screening and Molecular Docking
The resulting 3D-pharmacophores were used for 3D- database screening with the UNITY
program (Tripos, Inc.) in SYBYL7.1. The NCI-2000 database, integrated in SYBYL, with
about 250,000 compounds stored as 3D structures converted from their 2D forms by Concord,
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was screened for compounds matching the pharmacophores, using tolerance for HBA and HBD
features of 0.3Å and for HP of 0.8Å..
Selected compounds were docked to fibril sites 1 and 2 of the two Aβ models Aβ40m2_1.pdb
and Aβ40p2_10.pdb with AutoDock, using the methods described above, and ranked according
to their docking scores. Compounds with cLogP was <5 and molecular weight <500 were
considered if their binding energies were lower than the binding energy of LPFFD. Highest
priority was given to compounds selected several times in the UNITY searches with the
different pharmacophores.
5.6 Preparation of Aβ peptide and compounds for the aggregation assay
Aβ1–42 was synthesized using solid phase chemistry by the protein core at Yale University
(W.M. Keck Facility, University of Yale). 0.3 mg of lyophilized powder was dissolved in 200
μl of hexafluoro-2-propanol (Sigma-Aldrich) for 10–20 minutes at room temperature. Soluble
Aβ was made by drying the HFIP and adding H2O in a siliconized Eppendorf tube to obtain a
final peptide concentration of 60 uM. For the experiments Aβ was diluted to 3.3 μM in 0.1 mM
Tris in the absence and presence of selected small molecules at a one to one molar ratio.
Compounds were obtained in powder form from the stock collection of the Developmental
Therapeutics Program (DTP), NCI, Bethesda, MD (http://dtp.nci.nih.gov) and dissolved in
DMSO to 0.4 mM for storage at −20°C. They were diluted 100X in Hepes, pH 7.0, before
adding to the assay. The same amount of DMSO was added to the controls.
5.7. Assays for aggregation inhibition
The compounds were screened first with a medium throughput in vitro fluorometric assay based
on the fluorescence emission of thioflavin T (ThT) when bound to amyloid fibrils42. Soluble
Aβ peptide at a concentration of 3.3μM in 0.1M Tris buffer was incubated alone or with the
indicated concentrations of the compounds for 24h at 37°C. Aliquots (20 μl) of samples were
incubated 15 minutes at room temperature in 50 mM glycine, pH 9.2 and 2 μM ThT.
Fluorescence was measured at excitation wavelength of 435 nm with emission at 485 nm.
Compounds 1, 6 and 7 (3.3 μM) were further tested for their ability to dissassemble pre-formed
fibrillar Aβ after incubation for 24 hr. As control soluble (non-fibrillar) Aβ and fibrils incubated
alone were included. The quantity of fibrils was measured by ThT fluorescence. To rule out
that the compounds interfere with ThT fluorescence, the effect of the compounds alone on the
assay was measured.
Aβ aggregates were also assayed by sedimentation. After incubation with or without
compounds, samples were centrifuged at 16000×g for 10 min at 4°C. Soluble peptide was
measured in the supernatant by ELISA using the 4G8 anti-Aβ monoclonal antibody.
5.8. Neuronal toxicity assay
Compounds 1, 6 and 7 (3.3 μM) were incubated with soluble Aβ (3.3 μM) for 48 hr. Controls
were soluble Aβ incubated at the same concentration either with addition of the inactive
compound 1 or the same amount of DMSO (the final concentration of DMSO in all assays was
<0.1%). Aliquots of samples (10 μl) were added to 80% confluent mouse neuroblastoma cells
N2a, incubated 24h in a 96 well plate at 37°C in a humidified, 5% CO2 atmosphere. Cell
survival was assessed by the MTS assay (Promega). The combined MTS/PMS solution (20
μl) was added to the culture medium and the cells were incubated 1–4 h at 37°C in a humidified,
5% CO2 atmosphere. Absorbance was read at 490 nm.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.
Docking positions of 30 β-sheet breaker pentapeptides on two fibril structures of Aβ,
Aβ40m2_1.pdb (left), and Aβ40p2_1.pdb (right), colored according to their activities in
preventing Aβ aggregation (red, highest relative activities > 70% of LPFFD activity, or ln(Act)
> 4.25; green, lowest relative activities <=7% or ln(Act) < 2.0; yellow have intermediate
activities (70> Relative activity > 8; or 4.25 > (ln(Act) < 2). The top of the fibril is indicated
for orientation purposes.
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Fig. 2.
Fig. 2. A, B) Preferred docking sites for LPFFD (shown with CPK coloring) to the fibril
stuctures A) Aβ40m2_1.pdb and B) Aβ40p2_1.pdb.
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Fig. 3.
Pharmacophores designed based on the docking model of LPFFD to A, B) docking sites 1, 2
of the fibril structure Aβ40m2_1. C,D) docking sites 1,2 of the fibril structure Aβ40p2_1.
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Fig. 4.
Structures and NCI number of NCI compounds selected for bioassays.
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Fig. 5.
In vitro activity of selected compounds on Aβ fibrillogenesis. A: Chemical structure of two
putative β-sheet breaker mimetics: β-sheet breaker mimetic 6 (BSBM6) and β-sheet breaker
mimetic 7 (BSBM7), and the inactive C1 control compound. B: The effect of selected
compounds on Aβ amyloid formation was studied by incubation of soluble Aβ1–42 in the
absence or the presence of an equimolar concentration of the molecules. Amyloid formation
was measured by ThT, as described in Methods. Results are expressed as a percentage of fibrils
formed by the peptide incubated alone for 24h. The data was analyzed by student-t test by
comparing each result with the control of Aβ incubated alone. ***, P<0.001. C: The ability of
the compounds to disassemble pre-form fibrils was assessed by incubation of the molecules
with Aβ aggregates made by pre-incubation of Aβ1–42 alone. The amount of fibrils before and
after incubation with the compounds was studied by ThT. Results are expressed as a percentage
of fibrils remaining after incubation alone for 24h. The data was analyzed by student-t test by
comparing with the control of fibrils incubated alone. ***, P<0.001. D: The concentration-
dependent effect of BSBM6 and BSBM7 on Aβ aggregation was studied by incubating soluble
Aβ1–42 with various quantities of the compounds for 24h at 37°C. Formation of aggregates
was quantified by sedimentation assay, followed by ELISA, as described in Methods. The data
in panels B, C and D corresponds to the average ± standard error of three different experiments.
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Fig. 6.
The activity of selected compounds on preventing Aβ neurotoxicity was studied in cell cultures.
N2A cells were treated with soluble Aβ1–42 (3.3 μM) which was pre-incubated for 48h either
alone or in the presence of 3.3 μM of BSBM6, BSBM7 or C1. After 24h incubation with the
mixture peptide/compounds, cell viability was evaluated by the MTS assay. Data represent the
average ± standard error of 3 determinations and is expressed as the percentage of viability
obtained when cells were incubated alone for 24h. Data for the compounds was statistically
compared with cells incubated alone suing the student-t test. ** P<0.01; *** P<0.001.
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Figure 7.
Comparison, based on the the best ranked conformations (lowest binding scores) from
AutoDock, of the type of hydrogen bonds formed between atoms of the bad aggregation
inhibitors (A,B) and good ones (C,D) and the fibril. The side chains of the pentapeptides
LTicFFD (inactive) and LPFFD (active) are not shown. The hydrogen bonds between ligands
and fibril are indicated by red arrows (those that would be expected to break or weaken the β
sheet hydrogen bond network of the fibril) and blue arrows (those expected to enhance the
stability of the e β sheet hydrogen bond network). Yellow arrows indicate those close
interactions that should not affect β sheet hydrogen bond network.
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